Nalaganje...
Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
OBJECTIVE: The objective of this open-label, randomized study was to compare dose-dense paclitaxel plus carboplatin (PCdd) with dose-dense epirubicin and cyclophosphamide followed by paclitaxel (ECdd-P) as an adjuvant chemotherapy for early triple-negative breast cancer (TNBC). METHODS: We included...
Shranjeno v:
| izdano v: | Chin J Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
AME Publishing Company
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7491545/ https://ncbi.nlm.nih.gov/pubmed/32963461 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21147/j.issn.1000-9604.2020.04.06 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|